RNAC Q3 2020 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M

Gross Profit

$5M100.0% margin

Operating Income

-$14M-295.6% margin

Net Income

-$10M-209.4% margin

EPS (Diluted)

$-2.77

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$66M

Free Cash Flow

$65M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$181M

Total Liabilities

$188M

Stockholders' Equity

-$7M

Cash & Equivalents

$146M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$0	—
Gross Profit	$5M	$0	—
Operating Income	-$14M	-$12M	-16.4%
Net Income	-$10M	-$12M	+18.9%